The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 04, 2022

Filed:

Sep. 21, 2018
Applicant:

National Cancer Center, Gyeonggi-do, KR;

Inventors:

Yong-Doo Choi, Gyeonggi-do, KR;

Hyun-Jin Kim, Gyeonggi-do, KR;

Assignee:

National Cancer Center, Gyeonggi-Do, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); G01N 33/58 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); C07K 16/22 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0058 (2013.01); A61K 49/0028 (2013.01); A61K 49/0039 (2013.01); A61K 49/0043 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/2884 (2013.01); C07K 16/2887 (2013.01); C07K 16/3069 (2013.01); C07K 16/3092 (2013.01); C07K 16/32 (2013.01); G01N 33/57492 (2013.01); G01N 33/582 (2013.01); C07K 2317/77 (2013.01);
Abstract

The present invention relates to an antibody-fluorescent dye conjugate capable of cancer cell-specific fluorescence imaging diagnosis. The fluorescent dye comprises a covalently labeled antibody and is quenched by interaction with an amino acid residue such as tryptophan, tyrosine, histidine, and methionine in the antibody and upon binding of the antibody to an antigen present on a cell surface to emit fluorescence, whereby cells having a target antigen thereon can be imaged for diagnosis. When using the antibody-fluorescent dye conjugate according to the present invention during in vitro cell assays, high-throughput screening of cells, and cytodiagnosis based on microfluidics, the presence of cancer cells having a specific antigen expressed thereon can be detected at high specificity and sensitivity without a washing process, and the position of primary and metastatic cancer cells can be detected at high contrast within a short time.


Find Patent Forward Citations

Loading…